Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics

ACS Medicinal Chemistry Letters

Volumn 3, Issue 7, 2012, Pages 602-606

  Haddach, Mustapha ^a   Schwaebe, Michael K ^a   Michaux, Jerome ^a   Nagasawa, Johnny ^a   O'Brien, Sean E ^a   Whitten, Jeffrey P ^a   Pierre, Fabrice ^a   Kerdoncuff, Pauline ^a   Darjania, Levan ^a   Stansfield, Ryan ^a   Drygin, Denis ^a   Anderes, Kenna ^a   Proffitt, Chris ^a   Bliesath, Josh ^a   Siddiqui Jain, Adam ^a   Omori, May ^a   Huser, Nanni ^a   Rice, William G ^a   Ryckman, David M ^a  

^a Cylene Pharmaceuticals   (United States)

Author keywords

CX 5461; p53; RNA polymerase I; rRNA

Indexed keywords

2 (4 METHYL [1,4]DIAZEPAN 1 YL) 5 OXO 5H 7 THIA 1,11B DIAZA BENZO[C]FLUORENE 6 CARBOXYLIC ACID (5 METHYL PYRAZIN 2 YLMETHYL) AMIDE; ANTINEOPLASTIC AGENT; CX 5461; DNA DIRECTED RNA POLYMERASE; NUCLEOTIDYLTRANSFERASE INHIBITOR; RIBOSOME DNA; RIBOSOME RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; DNA TRANSCRIPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLASTIC LYMPHOMA; IN VIVO STUDY; MOUSE; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

THIA;

EID: 84863822813     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300110s     Document Type: Article

References (21)

1. Solimini, N. L.; Luo, J.; Elledge, S. J. Non-oncogene addiction and the stress phenotype of cancer cells Cell 2007, 130 (6) 986-988
2. Luo, J.; Solimini, N. L.; Elledge, S. J. Principles of cancer therapy: Oncogene and non-oncogene addiction Cell 2009, 136 (5) 823-837
3. Grummt, I. Life on a planet of its own: Regulation of RNA polymerase I transcription in the nucleolus Genes Dev. 2003, 17 (14) 1691-1702
4. Moss, T. At the crossroads of growth control; making ribosomal RNA Curr. Opin. Genet. Dev. 2004, 14 (2) 210-217
5. Russell, J.; Zomerdijk, J. C. The RNA polymerase I transcription machinery Biochem. Soc. Symp. 2006, 73, 203-216
6. Ruggero, D.; Pandolfi, P. P. Does the ribosome translate cancer? Nat. Rev. Cancer 2003, 3 (3) 179-192
7. Drygin, D.; Rice, W. G.; Grummt, I. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer Annu. Rev. Pharmacol. Toxicol. 2010, 50, 131-156
8. White, R. J. RNA polymerases I and III, growth control and cancer Nat. Rev. Mol. Cell Biol. 2005, 6 (1) 69-78
9. White, R. J. RNA polymerases I and III, non-coding RNAs and cancer Trends Genet. 2008, 24 (12) 622-629
10. Bywater, M.; Poortinga, G.; Cullinane, G.; Stanley, K.; Walker, R.; Drygin, D.; Anderes, K.; Johnstone, R.; McArthur, G.; Hannan, R. In RNA Polymerase I: A Novel Target in the Treatment of MYC-Driven Malignancy, AACR Special Conference on Protein and Cancer San Diego, CA, 2010; San Diego, CA, 2010.
11. Budde, A.; Grummt, I. p53 represses ribosomal gene transcription Oncogene 1999, 18 (4) 1119-1124
12. Zhai, W.; Comai, L. Repression of RNA polymerase I transcription by the tumor suppressor p53 Mol. Cell. Biol. 2000, 20 (16) 5930-5938
13. Deisenroth, C.; Zhang, Y. Ribosome biogenesis surveillance: Probing the ribosomal protein-Mdm2-p53 pathway Oncogene 2010, 29 (30) 4253-4260
14. Burger, K.; Muhl, B.; Harasim, T.; Rohrmoser, M.; Malamoussi, A.; Orban, M.; Kellner, M.; Gruber-Eber, A.; Kremmer, E.; Holzel, M.; Eick, D. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels J. Biol. Chem. 2010, 285 (16) 12416-12425
15. Drygin, D.; Lin, A.; Bliesath, J.; Ho, C. B.;, S.; Proffitt, C.; Omori, M.; Haddach, M.; Schwaebe, M.; Siddiqui-Jain, A.; Streiner, N.; Quin, J. E.; Sanij, E.; Bywater, M. J.; Hannan, R. D.; Ryckman, D.; Anderes, K.; Rice, W. G. RNA Polymerse I Targeting with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth Cancer Res. 2011, 71, 1418-1430
16. Smith, N. F.; Raynaud, F. I.; Workman, P. The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery Mol. Cancer Ther. 2007, 6 (2) 428-440
17. Smith, N. F.; Hayes, A.; Nutley, B. P.; Raynaud, F. I.; Workman, P. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice Cancer Chemother. Pharmacol. 2004, 54 (6) 475-486
18. Brown, N.; Jacoby, E. On scaffolds and hopping in medicinal chemistry Mini Rev. Med. Chem. 2006, 6 (11) 1217-1229
19. Chua, P. C.; Nagasawa, J. Y.; Nagasawa, J.; Pierre, F.; Schaebe, M. K.; Vialettes, A.; Whitten, J. P. A novel and efficient synthesis of 3-carboxy-4-oxo-1,8-naphthyridines using magnesium chloride Tetrahedron Lett. 2008, 49, 4437-4442
20. Miyamae, Y.; Zaizen, K.; Ohara, K.; Mine, Y.; Sasaki, Y. F. Detection of DNA lesions induced by chemical mutagens by the single cell electrophoresis (Comet) assay. 1. Relationship between the onset of DNA damage and the characteristics of mutagens Mutat. Res. 1998, 415 (3) 229-235
21. Gotz, C.; Montenarh, M. p53: DNA damage, DNA repair, and apoptosis Rev. Physiol. Biochem. Pharmacol. 1996, 127, 65-95